Hjem › Neuroendokrine tumorer › Florida
Neuroendokrine tumorer kliniske forsøg i Florida
12 studier for Neuroendokrine tumorer søger deltagere på steder i Florida.
Byer i Florida
Officiel studietekst (engelsk)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Mayo Clinic - Florida, Jacksonville
- AdventHealth Orlando, Orlando
- Moffitt Cancer Center, Tampa
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT06943755Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- University of Miami, Miami
- Moffitt Cancer Center, Tampa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT07087054Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Research Facility, Jacksonville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT07165132Project: Every Child for Younger Patients With Cancer
- Broward Health Medical Center, Fort Lauderdale
- Golisano Children's Hospital of Southwest Florida, Fort Myers
- UF Health Cancer Institute - Gainesville, Gainesville
- og 13 flere
RekruttererObservationsstudie
Op til 25 år · Alle køn · Opdateret 25. aug. 2026 · NCT02402244Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- University of Florida, Gainesville
RekruttererFase 1/2
Alder 18 til 99 · Alle køn · Opdateret 13. jul. 2026 · NCT05000294Integrated Cancer Repository for Cancer Research
- Florida Hospital Memorial Medical Center, Daytona Beach
- Florida Hospital DeLand, DeLand
- Florida Hospital FISH, Orange City
- og 2 flere
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 19 til 110 · Alle køn · Opdateret 29. jun. 2026 · NCT02012699CapTemY90 for Grade 2/3 NET Liver Metastases
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 4. jun. 2026 · NCT04339036A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Memorial Healthcare System, Hollywood
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 27. maj 2026 · NCT03093116Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Mayo Clinic, Jacksonville
- Biogenix Molecular, Miami
RekruttererFase 1/2
Alder 18 til 90 · Alle køn · Opdateret 14. maj 2026 · NCT05636618SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
- University of Miami, Miami
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. apr. 2026 · NCT06889493Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- Research Facility, Miami
- Research Facility, Tampa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. mar. 2026 · NCT05477576SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Jacksonville
- Massive Bio SYNERGY-AI site, Miami
- Massive Bio SYNERGY-AI site, Tampa
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.